RESUMEN
IMPACT STATEMENT: In this review, we address the potential of human-induced pluripotent stem cell-based hepatobiliary differentiation technology as a means to study human liver development and cell fate determination, and to model liver diseases in an effort to develop a new human-relevant preclinical platform for drug development.
Asunto(s)
Conductos Biliares/efectos de los fármacos , Desarrollo de Medicamentos/métodos , Células Madre Pluripotentes Inducidas/efectos de los fármacos , Hepatopatías/terapia , Hígado/efectos de los fármacos , Proteínas Adaptadoras Transductoras de Señales/fisiología , Adulto , Animales , Conductos Biliares/citología , Diferenciación Celular , Línea Celular , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Evaluación Preclínica de Medicamentos/métodos , Cuerpos Embrioides/efectos de los fármacos , Proteínas Hedgehog/fisiología , Hepatocitos/efectos de los fármacos , Humanos , Técnicas In Vitro , Células Madre Pluripotentes Inducidas/citología , Hígado/citología , Hepatopatías/patología , Modelos Animales , Transducción de Señal/efectos de los fármacos , Factores de Transcripción/fisiología , Proteínas Señalizadoras YAPRESUMEN
The recent advances in the induced pluripotent stem cell (iPSC) research have significantly changed our perspectives on regenerative medicine by providing researchers with a unique tool to derive disease-specific stem cells for study. In this review, we describe the human iPSC generation from developmentally diverse origins (i.e. endoderm-, mesoderm-, and ectoderm- tissue derived human iPSCs) and multistage hepatic differentiation protocols, and discuss both basic and clinical applications of these cells including disease modeling, drug toxicity screening/drug discovery, gene therapy and cell replacement therapy.